Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
Belite Bio (NASDAQ: BLTE) has secured US$28.75 million through the exercise of warrants at US$44.14 per share for 651,380 ordinary shares. In exchange for this immediate cash exercise, the company will issue new unregistered warrants for the same number of shares with an exercise price of US$70.00 per share, valid for five years. If these new warrants are fully exercised, they could generate additional gross proceeds of approximately US$45.6 million. The company plans to use the proceeds for general corporate purposes.
Belite Bio (NASDAQ: BLTE) ha ottenuto 28,75 milioni di dollari USA attraverso l'esercizio di warrant a 44,14 dollari USA per azione per 651.380 azioni ordinarie. In cambio di questo esercizio immediato in contante, l'azienda emetterà nuovi warrant non registrati per lo stesso numero di azioni con un prezzo di esercizio di 70,00 dollari USA per azione, validi per cinque anni. Se questi nuovi warrant vengono interamente esercitati, potrebbero generare ulteriori proventi lordi di circa 45,6 milioni di dollari USA. L'azienda prevede di utilizzare i proventi per scopi aziendali generali.
Belite Bio (NASDAQ: BLTE) ha asegurado 28.75 millones de dólares EE. UU. a través del ejercicio de warrants a 44.14 dólares EE. UU. por acción para 651,380 acciones ordinarias. A cambio de este ejercicio inmediato en efectivo, la compañía emitirá nuevos warrants no registrados por el mismo número de acciones con un precio de ejercicio de 70.00 dólares EE. UU. por acción, válidos por cinco años. Si estos nuevos warrants se ejercen en su totalidad, podrían generar ingresos brutos adicionales de aproximadamente 45.6 millones de dólares EE. UU.. La empresa planea utilizar los ingresos para fines corporativos generales.
Belite Bio (NASDAQ: BLTE)는 2875만 달러를 확보했습니다. 이는 651,380주에 대해 주당 44.14달러의 워런트를 행사한 결과입니다. 이 즉각적인 현금 행사에 대한 대가로, 회사는 같은 수의 주식에 대해 주당 70.00달러의 행사 가격을 가진 새로운 비등록 워런트를 발행할 것입니다. 이러한 워런트는 5년간 유효합니다. 이 새로운 워런트가 모두 행사되면, 약 4560만 달러의 추가 총 수익을 발생시킬 수 있습니다. 회사는 이 수익을 일반 기업 용도로 사용할 계획입니다.
Belite Bio (NASDAQ: BLTE) a obtenu 28,75 millions de dollars US grâce à l'exercice de bons de souscription au prix de 44,14 dollars US par action pour 651 380 actions ordinaires. En échange de cet exercice immédiat en espèces, l'entreprise émettra de nouveaux bons de souscription non enregistrés pour le même nombre d'actions avec un prix d'exercice de 70,00 dollars US par action, valables pendant cinq ans. Si ces nouveaux bons de souscription sont entièrement exercés, ils pourraient générer des produits bruts supplémentaires d'environ 45,6 millions de dollars US. L'entreprise prévoit d'utiliser les fonds pour des besoins d'entreprise généraux.
Belite Bio (NASDAQ: BLTE) hat 28,75 Millionen US-Dollar durch die Ausübung von Warrants zu einem Preis von 44,14 US-Dollar pro Aktie für 651.380 Stammaktien gesichert. Im Austausch für diese sofortige Barausübung wird das Unternehmen neue nicht registrierte Warrants für die gleiche Anzahl von Aktien mit einem Ausübungspreis von 70,00 US-Dollar pro Aktie ausgeben, die fünf Jahre gültig sind. Wenn diese neuen Warrants vollständig ausgeübt werden, könnten sie zusätzliche Bruttoeinnahmen von ca. 45,6 Millionen US-Dollar generieren. Das Unternehmen plant, die Einnahmen für allgemeine Unternehmenszwecke zu verwenden.
- Immediate capital raise of US$28.75 million through warrant exercise
- Potential additional future proceeds of US$45.6 million from new warrants
- Successfully executed financing strategy without direct share dilution
- Future dilution potential if new warrants are exercised
- Higher exercise price of US$70.00 for new warrants may limit likelihood of exercise
Insights
This warrant exercise brings an immediate
The timing and structure of this deal is strategic - by exercising now rather than waiting, the company secures immediate capital while maintaining upside potential through the new warrants. This move helps extend their cash runway without diluting existing shareholders through a traditional equity offering, which is particularly valuable for clinical-stage biotech companies focused on expensive drug development programs in retinal diseases.
SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 651,380 ordinary shares of the Company originally issued in April 2024, at an exercise price of US
The ordinary shares issuable upon exercise of the warrants are registered pursuant to effective registration statement on Form F-3 (File No. 333-272125) filed with the SEC on May 30, 2023. The offering is expected to close on or about November 4, 2024, subject to satisfaction of customary closing conditions.
In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase up to 651,380 ordinary shares. The new warrants will have an exercise price of US
The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”), have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from such registration requirements.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs such as (i) atrophic age-related macular degeneration (AMD), commonly known as Geographic Atrophy (GA) in advanced dry AMD, and (ii) autosomal recessive Stargardt disease type 1, or STGD1, in addition to specific metabolic diseases. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, and any other statements containing the words “expect”, “hope” and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to the closing date of the warrant exercise and issuance of new warrants or the aggregate proceeds to be received by the Company if all such new warrants were exercised in full, as well as those risks more fully discussed in the “Risk Factors” section in Belite Bio’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Media and Investor Relations Contact:
Jennifer Wu / ir@belitebio.com
Julie Fallon / belite@argotpartners.com
FAQ
How much did Belite Bio (BLTE) raise from warrant exercise in November 2024?
What is the exercise price of BLTE's new warrants issued in November 2024?